$BLCO

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Bausch + Lomb (BLCO) received European CE Mark approval for SeeLyra, a next-gen femtosecond laser. It will launch in Europe soon and seek global approvals, including in the U.S. SeeLyra aids in cataract, LASIK, and corneal surgeries. BLCO shares closed at $17.55 on NYSE.

Bausch + Lomb (BLCO) reported positive real-world outcomes for its intraocular lenses, supporting its products' safety and effectiveness. The company's stock has seen significant gains, with a 20.19% total return over the past year. Investors are evaluating whether the current valuation, at $18.04 per share, leaves room for further upside, given a fair value estimate of $39.23 per share and ongoing governance concerns.

Bausch + Lomb (NYSE/TSX: BLCO) published research in Ophthalmology and Therapy showing enVista Aspire and enVista Aspire toric intraocular lenses provide good distance and intermediate vision in cataract patients. The study involved 84 patients and found high rates of visual acuity improvement with no serious adverse events. The lenses are designed to meet modern digital demands.

Healthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.

Bausch + Lomb (NYSE/TSX: BLCO) announced two eye health therapies will advance to new trials. A dual-action eye drop for dry eye disease will move to Phase 3 after showing significant results at Day 15. An ocular surface pain treatment, BL1332, showed positive Phase 1b results and is in Phase 2 trials. Combined potential peak sales are estimated at over $2 billion.

Munsch Frederick (SVP, Controller and CAO) sold 52,900 shares of Bausch & Lomb Corp (BLCO) at $16.78 ($0.89M total) on 2026-08-10.

Bausch + Lomb (NYSE:BLCO) reported Q2 2026 revenue of $1.39B and narrowed its net loss to $14M. The company raised full-year 2026 revenue guidance to $5.44B to $5.54B. It also appointed four new directors after four resignations. The article assesses how the outlook and board changes may affect BLCO’s investment case.

VON ESCHENBACH ANDREW C. sold 18,559 shares of Bausch & Lomb Corp (BLCO) at an average of $16.53 ($16.50–$16.58, $0.31M total) across 2 trades over 2026-08-06 to 2026-08-07.

Bausch Health Companies Inc. (NYSE:BHC) said CEO Thomas J. Appio was appointed to the board of Bausch + Lomb Corporation (NYSE:BLCO), effective Aug. 5, 2026. Other directors also joined, replacing several who resigned. Bausch Health said it holds about 87% of Bausch + Lomb’s common shares indirectly and supports its strategy.